EP1846012A1 - Extrait végétal stabilisé et applications thérapeutiques - Google Patents

Extrait végétal stabilisé et applications thérapeutiques

Info

Publication number
EP1846012A1
EP1846012A1 EP06709574A EP06709574A EP1846012A1 EP 1846012 A1 EP1846012 A1 EP 1846012A1 EP 06709574 A EP06709574 A EP 06709574A EP 06709574 A EP06709574 A EP 06709574A EP 1846012 A1 EP1846012 A1 EP 1846012A1
Authority
EP
European Patent Office
Prior art keywords
extract
agents
components
stabilised
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06709574A
Other languages
German (de)
English (en)
Inventor
Julia Diederichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veritron Ltd
Original Assignee
Veritron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veritron Ltd filed Critical Veritron Ltd
Publication of EP1846012A1 publication Critical patent/EP1846012A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to a stabilised plant extract and its therapeutic use.
  • Background of the Invention The therapeutic effect of herbs and other plants has been acknowledged for millennia. There has however been little rational analysis of such effects. This is despite the fact that natural products are of increasing interest, not least because of the possibility that they may have specific therapeutic effects, without major sideeffects.
  • a composition having remarkable therapeutic effects, including the treatment of tumours, is disclosed in WO03/101479.
  • One of the components of the most preferred embodiment is a camomile extract which is described as an anti-irritant. No pharmaceutical property is ascribed to the extract. It is suggested that the aqueous extract (for which a particular extraction procedure is given) has a palliative effect when administered by the preferred route, i.e. injection.
  • an aqueous composition according to the present invention may comprise a plant extract, obtainable by aqueous extraction, and such a water-soluble agent.
  • a product of the invention may have utility in a new process for the preparation of the composition described in WO03/101479.
  • Description of Preferred Embodiments Plants that may be extracted for use in the invention include Matricaria
  • the extract may be obtained from any part of the plant, e.g. the stem, leaves orflowers. An aqueous extract is preferred. The available evidence suggests that an extract of such herbal substances obtained as described below may cause an increase in the level of the cytokine IL-6. This is a good measure of the desirable properties of this extract.
  • cytokines that may be affected, in order to obtain the desirable properties of the invention, are other interleukins such as IL-7, IL-8, IL-9 and IL-10, and also tumour necrosis factor (TNF).
  • the extract may be obtained by any suitable procedure, including methods known to those of ordinary skill in the art.
  • the extract may be obtained by using an aqueous or organic medium, and separated from other components by filtration, chromatography etc.
  • a material that may be used in the invention is derived from the dried flower heads of the composite plant Matricaria chamomilla, the seeds of the plant Nigella Sativa, the gum of the plant Acacia Senegal, or one or more materials therein, include polysaccharides, glycoproteins, volatile oils, azolene, anthemic acid, apogenin, glycosides and other substances.
  • the preferred water-soluble chelating agent is PVP.
  • Other such agents may be suitable for use in the invention.
  • the amount of the chelating agent that can be used will be dependent on factors such as the component to be stabilised, other components and the intended use. A suitable amount can readily be determined by one skilled in the art.
  • An aqueous composition may comprise one or more components as described in WO03/101479, the content of which is incorporated herein by reference.
  • One such component for use in the invention is an antioxidant. The function of this component may be to prevent the formation of S-S bridges by oxidation of cysteine residues. Disulfide linkages are caused by many oxidising agents, and cause loss of enzymatic activity.
  • the antioxidant may inhibit the production of oxygen radicals (free radicals) as a by-product of the normal metabolism of oxygen.
  • oxygen radicals are very damaging to cell membranes, proteins, lipids and DNA. Oxidative damage accumulates with age and is considered to be a major contributor to ageing and the development of degenerative diseases (e.g. cancer, cardiovascular disease, immune system decline, etc).
  • Suitable antioxidants for use in the invention are small molecules such as vitamin C, A and E. It will be appreciated that a suitable precursor of any such compound may be used, e.g. ⁇ -carotene.
  • the preferred antioxidant for use in this invention is vitamin C, e.g. as Sodium ascorbate or ascorbic acid.
  • a suitable dosage of this component is 1 to 500 mg/kg/day.
  • this component may comprise one or more components of vitamin B.
  • vitamin B many enzymes catalyse reaction of their substrates only in the presence of a specific non-protein molecule, i.e. a coenzyme.
  • Coenzymes frequently contain B vitamins as part of their structure.
  • B1 thiamine hydrochloride
  • B2 riboflavin sodium phosphate
  • PP nicotinamide
  • B6 pyridoxine hydrochloride
  • B5 didoxine hydrochloride
  • the amount of each such component is, for example, 0.1 to 50 mg/kg/day.
  • a second component for use according to the present invention is a metal salt that provides metal ions, in vivo.
  • the nature of the anion is not critical, and will generally be chosen to be non-toxic and of suitable solubility or other appropriate compatibility with other components of the medicament.
  • Many metal ions act as positive modifiers, and certain enzymes require the presence of metal ion for full activity.
  • the function of the metal ion may be to complement the coenzyme.
  • the ion may be, for example, Na, K or multivalent such as Fe, Mo, Mg, Mn, Ca, Zn, Cu or Co. This may be in the form of a salt, of which many examples are known, e.g.
  • a preferred component of this type is Calcium Gluceptate.
  • a typical dosage of this component is 1 to 1000 mg/kg/day.
  • a third component for use according to the invention may be an agent that increases the permeability of cell membranes or otherwise enhances transport, e.g. by action on receptors.
  • This material may enhance the ability of the cells that need treatment to receive the other active material or materials that may be included in the novel medicament, especially in human therapy (it may not be required in veterinary medicine).
  • a preferred agent of this type is insulin or a growth hormone.
  • a typical dosage of insulin is 1 to 1000 IU/kg/day.
  • Another component is an antihistamine.
  • Such a material can not only prevent or reduce abnormal reactions, especially allergic reaction, but also prevent the accumulation of substances which block transport, e.g. by binding to cell membrane receptors.
  • antihistamines work by competing with histamine released by mast cells and basophils for histamine receptors on the mucosa of the eyes, nose, bronchial airways and skin.
  • the antihistamine binds to the receptor and prevents histamine attachment, thereby blocking the effect of histamine in the tissues.
  • Antihistamine drugs counteract the physiological effects of histamine production, in allergic reactions and colds.
  • Antihistamines can be divided into classical and non-sedating antihistamines. There are many examples of such compounds, including acrivastine, azatadine, azelastine, brompheniramine, carbinoxamine, cetirizine, chlorpheniramine, clemastine fumarate, cyproheptadine, diphenhydramine, doxepin, hydroxyzine, fexofenadine, loratadine, meclizine, phenindamine, promethazine, pyrilamine and tipolidine.
  • a preferred material for use in the invention is chlorpheniramine maleate.
  • a suitable dosage of such a component is 0.1 to 50 mg/kg/day.
  • honey may comprisecomponents that provide an activity that is analogous to that obtained from the components of the plants described above.
  • vitamin A may be to preserve the integrity of epithelial tissue, to play a role in protein synthesis, and to stabilise cell membranes and also subcellular membranes.
  • a medicament for use in the invention may comprise other components, depending on the intended effect, the nature of the formulation, the route of administration, and other factors that are known to those skilled in the art.
  • the medicament may be formulated in water, e.g. to provide an aqueous solution or suspension suitable for injection. It may be desirable to include in any such formulation one or more additional substances that aid dissolution or suspension of active components, such as an organic or a polar solvent.
  • the composition may comprise conventional excipients, for example, phenol (which acts as a preservative).
  • compositions for use according to the invention can be formulated by methods known to those skilled in the art.
  • Pharmaceutically acceptable components should be used.
  • pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding factors such as formulation, stability, patient acceptance and bioavailability.
  • the pharmaceutical composition containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients such as, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated, to form osmotic therapeutic tablets for control release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin or olive oil.
  • the composition may be an aqueous solution or suspension. It may contain the active materials in admixture with suitable excipients.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example a naturally occurring phosphatide such as lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol, such as a polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.
  • suspending agents for example sodium carboxymethylcellulose, methyl
  • Aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above
  • flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as Ascorbic Acid or Sodium ascorbate or ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, sorbitol
  • a pharmaceutical composition for use in the invention may also be in the form of an oil-in-water emulsion.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated using suitable dispersing or wetting agents and suspending agents, examples of which have been mentioned above.
  • a sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
  • compositions may also be administered in the form of suppositories for rectal administration of the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • compositions are in the form of, for example, creams, ointments, jellies, solutions or suspensions.
  • topical application includes mouth washes and gargles.
  • composition of the invention may be given by injection. Intramuscular injection is preferred, although any parenteral administration is suitable.
  • composition is given orally, although insulin should not usually be included in an oral formulation. Oral administration may be particularly preferred for veterinary medicine.
  • composition of the invention may be prepared simply by mixing the components, preferably using water for injection. Such a preparation is described in the following Example (which illustrates the invention).
  • a Kollidon solution was prepared by dissolving 213.3 g Kollidon 17PF in 266.6 g water for injection, with stirring, until a clear solution was obtained. 2.67 g 0.5 NaOH was added, with stirring, to a pH of between 7.0 and 7.4. A clear, colourless solution was obtained.
  • a vitamin mixture was prepared by dissolving the Dexpanthenol, Nicotinamide, Pyridoxine HCI, Rivoflavine Na Phosphate, Thiamine CI-HCI and Chlorpheniramine Maleate in 71.08 g water for injection, with stirring, for 20 minutes. 211.17 g of the Kollidon solution was added with stirring, for 10 minutes. A clear yellow-orange solution was obtained. The vessel was closed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Un extrait végétal, obtenu par extraction aqueuse, est stabilisé par la présence d'un agent hydrosoluble susceptible de chélater ledit extrait ou un composant dudit extrait.
EP06709574A 2005-01-26 2006-01-26 Extrait végétal stabilisé et applications thérapeutiques Withdrawn EP1846012A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501654.8A GB0501654D0 (en) 2005-01-26 2005-01-26 Stabilised plant extract
PCT/GB2006/000265 WO2006079815A1 (fr) 2005-01-26 2006-01-26 Extrait végétal stabilisé et applications thérapeutiques

Publications (1)

Publication Number Publication Date
EP1846012A1 true EP1846012A1 (fr) 2007-10-24

Family

ID=34259735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06709574A Withdrawn EP1846012A1 (fr) 2005-01-26 2006-01-26 Extrait végétal stabilisé et applications thérapeutiques

Country Status (7)

Country Link
EP (1) EP1846012A1 (fr)
JP (1) JP2008528563A (fr)
CN (1) CN101141971A (fr)
CA (1) CA2595348A1 (fr)
GB (1) GB0501654D0 (fr)
MX (1) MX2007008920A (fr)
WO (1) WO2006079815A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482711A (en) * 1993-08-25 1996-01-09 Medenica; Rajko D. Use of Nigella sativa to increase immune function
JPH07101836A (ja) * 1993-09-29 1995-04-18 Hoyu Co Ltd 毛髪処理剤
JP3864431B2 (ja) * 1995-06-12 2006-12-27 ゼリア新薬工業株式会社 カンゾウの抽出物を配合した安定な液剤
JP3696965B2 (ja) * 1996-03-04 2005-09-21 日本メナード化粧品株式会社 化粧料用痩身剤組成物
CH690817A5 (de) * 1996-09-03 2001-01-31 Flachsmann Ag Emil Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes.
JP3570482B2 (ja) * 1997-12-02 2004-09-29 ライオン株式会社 歯磨組成物及び苦味抑制方法
AU2002235145A1 (en) * 2000-11-27 2002-06-03 Conagra Foods, Inc. Stabilization method and composition utilizing an amphoteric polymer
CN1615146A (zh) * 2001-11-26 2005-05-11 芬策尔贝格有限两合公司 生姜提取物制剂
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006079815A1 *

Also Published As

Publication number Publication date
JP2008528563A (ja) 2008-07-31
CA2595348A1 (fr) 2006-08-03
MX2007008920A (es) 2007-09-13
CN101141971A (zh) 2008-03-12
WO2006079815A1 (fr) 2006-08-03
GB0501654D0 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
US6485760B2 (en) Method for inhibiting increase of blood sugar level or lowering blood sugar level with a lagerstroemia extract
US9775910B2 (en) Stable aqueous suspension
AU2007203159B2 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
ES2543708T3 (es) Composiciones que comprenden galactomanano y un proceso de las mismas
WO1989000427A1 (fr) Utilisation pharmaceutique therapeutique d'un derive de glutathion
US20110165262A1 (en) Reducing drug dependence or addiction
CN101254217B (zh) 一种红豆杉树可再生部分的提取物的制备方法及该提取物在制备口服抗癌药物中的应用
EP2558084B1 (fr) Combinaison du vitamin k et de l'amide nicotinique pour l'utilisation dans des maladies qui impliquent une calcification extra-osseuse
DE19823679C2 (de) Verwendung von Crataegus-Zubereitungen zur Prophylaxe und Therapie neoplastischer Erkrankungen
JP2002205949A (ja) 代謝異常改善方法およびそのための組成物
US20090175970A1 (en) Stabilized Plant Extract and Its Therapeutic Use
EP1846012A1 (fr) Extrait végétal stabilisé et applications thérapeutiques
KR102234860B1 (ko) 싸리 추출물을 포함하는 근위축 예방 및 치료용 조성물
KR20190083770A (ko) 밀크시슬을 포함하는 용출율이 향상된 간 질환 예방 및 치료용 조성물
JP2007161667A (ja) 血糖上昇を抑制する組成物、薬剤及び機能性食品
EP0950411B1 (fr) Procédé pour la préparation d'un extrait d'écorce de Copalchi et l'utilisation des néoflavonoides pour le traitement des diabetes
US10864174B2 (en) Method maintaining iron homeostasis with shogaols
BAMGBADE et al. Charlotte Mungho TATA, Marthe Carine Djuidje FOTSING and Derek Tantoh NDINTEH. Antidiabetic Potential of The Leaf Extracts of Phragmanthera incana (Schum.) Balle Harvested on Albizia lebbeck
US20210106636A1 (en) Pharmaceutical composition comprising cannabinoid
CN113633674A (zh) 一种兽用制剂多穗石柯口服液及其制备方法
CN112457428A (zh) 野生云南山楂多糖的制备与降脂和抗氧化应用
CN116139183A (zh) 一种具有延缓衰老作用的猪毛菜提取物及其应用
CN112675215A (zh) 一种含有nmn的抗衰老制剂及其制备方法
KR20130009506A (ko) 운동수행능력 증강 및 피로억제용 쿠커비테인 및 여주추출물, 및 이를 함유하는 조성물
KR20040088340A (ko) 알록산 투여로 유발된 고혈당에 있어서 혈중 글루코오스 저하를 유도하는 한약재 조성물 및 사용용도

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070823

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20071116

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130416